Back to Agenda
Session 3 Track E: Safety and Risk Mitigation (REMS) and the MSL
Session Chair(s)
Carrie C. Murray, MSN
Director, Global Brand Manager
Bayer HealthCare Pharmaceuticals, United States
During this session we will explore Risk Evaluation and Mitigation Strategies (REMS) and how MSLs contribute to pharmacovigilance initiatives. The following questions will be explored by a panel of experts:
• What is REMS and why are they important for MSLs?
• How are MSLs involved and what value does MSL involvement bring?
• What type of training is required to make REMS effective?
• How is MSL involvement documented and shared internally?
• What are best practices in partnerships between MSLs and pharmacovigilance teams?
Learning Objective : At the conclusion of this session, participants should be able to:
• Describe what REMS are and the expectations for pharmaceutical/biotech companies
• Examine implications for MSLs in participation in REMS programs
• Discuss solutions for partnerships between field based medical teams and pharmacovigilance
Speaker(s)
Faculty
Carrie C. Murray, MSN
Bayer HealthCare Pharmaceuticals, United States
Director, Global Brand Manager
Kimberly Boothe, PharmD, MHA
Yale New Haven Hospital, United States
Director, Pharmacy
Faculty
Kimberly Johnson, PharmD
Eli Lilly and Company, United States
Field Medical Advisor
Have an account?